Table 1.
Distribution of selected characteristics and clinical data for study patients with non–small-cell lung cancer*
| Characteristic | White patients (N = 558) | African American patients (N = 173) |
|---|---|---|
| Age, y (mean ± SD) | 66.4 ± 9.9 | 63.2 ± 9.2 |
| Male | 66.3 ± 9.8 | 64.0 ± 8.3 |
| Female | 66.6 ± 10.1 | 62.5 ± 10.1 |
| Sex, No. (%) | ||
| Male | 317 (56.8) | 88 (50.9) |
| Female | 241 (43.2) | 85 (49.1) |
| Smoking status, No. (%)† | ||
| Never | 36 (7.2) | 11 (6.4) |
| Former | 218 (43.8) | 60 (34.7) |
| Current | 244 (49.0) | 102 (58.9) |
| Pack-years‡ | ||
| <28.6, No. of patients (<25th percentile) | 138 (24.7) | 66 (38.2) |
| 28.6–64.8, No. of patients (25th–75th percentile) | 276 (49.5) | 75 (43.4) |
| >64.8, No. of patients (>75th percentile) | 144 (25.8) | 32 (18.5) |
| Tumor type, No. | ||
| Adenocarcinoma | 217 | 57 |
| Squamous cell carcinoma | 93 | 40 |
| NSCLC§ | 172 | 61 |
| Stage,† No. (%) | ||
| I–II | 365 (67.3) | 89 (56.0) |
| III–IV | 177 (32.7) | 70 (44.0) |
| Follow-up | ||
| Cumulative survival rate, % (95% CI)‖ | 27.3 (15.0 to 41.3) | 17.2 (7.1 to 30.9) |
| Median follow-up, mo (95% CI)¶ | 45.0 (40.8 to 48.9) | 43.9 (34.8 to 51.5) |
*
SD = standard deviation; NSCLC = non–small-cell lung cancer; CI = confidence interval.
†
Patients with missing data were not included.
‡
Smokers were categorized by using the 25th and 75th percentile pack-year values of the white patients.
§
Histologic subtype data were not available for all NSCLC tumors.
‖
The follow-up period was 20 years.
¶
Median survival months of patients who were alive at the end of follow-up.